Improving Management of Patients at High Risk for Osteoporotic Fractures

Merck Sharp & Dohme LLC0 sites4,266 target enrollmentSeptember 2004

ConditionsOsteoporosis

Overview

Phase: N/A
Intervention: Not specified
Conditions: Osteoporosis
Sponsor: Merck Sharp & Dohme LLC
Enrollment: 4266
Primary Endpoint: A composite measure of bone mineral density (BMD) testing and/or osteoporosis medications prescriptions.
Status: Completed
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The purpose of this study is to assess the impact of disease management interventions on percent receiving a bone densitometry test and percent appropriately prescribed a medication for osteoporosis.

Registry

clinicaltrials.gov

Start Date

September 2004

End Date

June 2005

Last Updated

10 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Merck Sharp & Dohme LLC

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Members of the Horizon Blue Cross Blue Shield of New Jersey who are at risk for osteoporosis based on age (women age 65 or older, men and women age 45 or older who have a history of fragility fracture or have a history of taking oral glucocorticoids over 3 months).